Services on Demand
- Cited by SciELO
- Access statistics
- Cited by Google
- Similars in SciELO
- Similars in Google
Print version ISSN 0021-7557
J. Pediatr. (Rio J.) vol.86 no.4 Porto Alegre July/Aug. 2010
Spinal muscular atrophy: diagnosis, treatment and future prospects
Mariana T. C. BaioniI; Celia R. AmbielII
IEspecialista, Fisiologia Humana,
Universidade Estadual de Maringá (UEM), Maringá, PR, Brazil
IIDoutora, Biologia Celular, Professora, Fisiologia Humana, UEM, Maringá, PR, Brazil
OBJECTIVE: To report on recent genetic
and molecular discoveries and on future prospects for the treatment of spinal
muscular atrophy (SMA), thereby helping healthcare professionals to make a quick
diagnosis and provide appropriate and timely therapeutic support.
SOURCES: Information was collected from scientific articles published in the last 2 decades, retrieved from the databases SciELO, PubMed, and MEDLINE.
SUMMARY OF THE FINDINGS: SMA is a neurodegenerative disorder with autosomal recessive genetic heredity. It is caused by a homozygous deletion of the survival motor neuron (SMN1) gene. This genetic alteration results in reduced levels of the SMN protein, leading to degeneration of alpha motor neurons of the spinal cord and resulting in muscle weakness and progressive symmetrical proximal paralysis. It is known that basic nutritional and respiratory care and physiotherapy can be important to delaying disease progression and prolonging patients' lives. Several drugs are being tested, some new, others, such as valproic acid, already known; paralysis can be halted, but not reversed.
CONCLUSIONS: SMA is a difficult to diagnose disorder, because it is little known, and treatment is uncertain. Pharmacological treatments and supportive therapies are not yet able to recover motor neurons or muscle cells that have already been lost, but are aimed at delaying disease progression and improving patients' residual muscle function, as well as offering better quality of life and life expectancy.
Keywords: Spinal muscular atrophy, motor neuron, therapy, SMN1 gene, SMN protein, valproic acid.
Spinal muscular atrophy (SMA) is a neurodegenerative disease with autosomal recessive heredity. After cystic fibrosis (1:6,000), SMA is the next most fatal disease with this genetic profile, with an incidence of 1:6,000 to 1:10,000 births.1 The frequency of carriers (heterozygotes) is one in 40 to 60 people.2
This disease is caused by a homozygous mutation or deletion of the survival motor neuron gene 1 (SMN1), which should be located in the telomeric region of chromosome 5q13. The principal determinant of severity is the number of copies of SMN2, a gene that is similar to SMN1 and is located in the centromeric region.3
This genetic alteration to the SMN1 gene is responsible for a reduction in survival motor neuron (SMN) protein. The SMN2 gene does not completely compensate for the absence of SMN1 expression because it only produces 25% of SMN protein.4 The lack of the SMN protein leads to degeneration of alpha (α) motor neurons located in the ventral horn of the spinal cord, which leads to progressive and symmetrical muscle weakness and paralysis.2
Clinical classification of SMA is based on age at onset and maximum motor function acquired, with the following categories: 1) severe (type I, severe SMA or Werdnig-Hoffmann disease); 2) intermediate (type II or chronic SMA); 3) mild (type III, juvenile SMA or Kugelberg-Welander disease); and 4) type IV (adult SMA).3 Other authors5-7 classify SMA into just three categories: severe, intermediate and mild.
SMA is a difficult disorder to diagnose and treatment is uncertain. Diagnosis is based on evidence, both electrophysiological and histological, of denervation of the muscle.3 Nowadays, diagnosis is confirmed by molecular analysis to demonstrate an absent SMN1 gene exon 7.2
Since this is a progressive neurodegenerative disease, patients with SMA require special care, which can halt disease progression and prolong their lives. The objective of this bibliographic review article is to describe the clinical and laboratory profile of SMA patients and report on recent genetic and molecular discoveries and the future prospects for treatment, thereby aiding health professionals to make rapid diagnoses and provide early and appropriate therapeutic support.
Classification of SMA
There are four SMA classifications, based on age at disease onset and maximum motor function acquired.
Type I SMA: (also known as severe SMA, Werdnig-Hoffmann disease or acute SMA) is characterized by early onset (between 0 and 6 months of age), by a failure to acquire the ability to sit up and by very short life expectancy (less than 2 years).3 Children diagnosed with this form have very little control of their heads and cough and cry weakly. They lose the ability to swallow and feed before they reach 1 year of age. Trunk and limb weakness normally spreads to the intercostal muscles, making it unlikely that a normal respiratory cycle will develop. Although the intercostal muscles are affected, the diaphragm is initially spared. The risk of early mortality is usually associated with bulbar dysfunction and respiratory complications.8 Historically, these children have a short life expectancy (less than 2 years), but, thanks to improved clinical care, over recent years survival has improved.9
Type II SMA: (or chronic SMA) generally becomes symptomatic at around 6 to 18 months, but it may emerge earlier. Some patients classified as having type II SMA are able to sit up unaided while others can remain sitting if they are positioned, but cannot sit up unaided.3 Better developed patients are able to remain standing if provided with support, but will nevertheless be unable to learn to walk. Bulbar weakness, combined with swallowing difficulties, can lead to reduced weight gain in some children. Furthermore, these patients may have problems with coughing and with cleaning secretions from the trachea, may have fine trembling (known as fasciculation) and can suffer from scoliosis and contractures as they age.8 Life expectancy is around 10 to 40 years.3,8
Type III SMA: (also known as juvenile SMA or Kugelberg-Welander syndrome) onset is after 18 months, but the actual age varies greatly. According to Wirth et al.,10 when the disease emerges before 3 years of age it is classified as Type IIIa SMA, whereas when onset is later, it is called Type IIIb SMA. The difference between the two is preservation of the ability to walk. Patients with Type IIIa are able to walk until they are 20, while Type IIIb patients will be able to walk for their whole lives.11 Problems with swallowing, coughing or nocturnal hypoventilation are less common than in patients with Type II, but may still be observed. As they age, these patients may develop scoliosis. The principal characteristic of these patients is that they are able to walk independently, and life expectancy is indeterminate.3
Type IV SMA: there is no consensus on the age of onset of Type IV SMA. Russman3 reports that it emerges after 10 years of age, whereas Wang et al.8 state that weakness normally emerges during the second or third decade of life, or at about 30 years of age. Motor function involvement is mild and there are no problems with deglutition or respiration. These patients are able to walk normally and have normal life expectancy.3,8
Clinical features of SMA
Since only α motor neurons are lost progressively, only motor function is compromised and sensory neurons are unaffected. This loss of function leads to weakness and to progressive symmetrical atrophy of the proximal voluntary muscles of the legs, arms and, sometimes, the trunk, as the disease progresses.8
A number of unusual clinical features are observed in SMA. One of these is the distribution of muscle weakness, which is more compatible with a myopathic disorder than with a neurogenic disorder.12 Proximal muscles are more involved than distal muscles, legs are more affected than arms and arms are more affected than the face and diaphragm.8,12 In other words, muscle weakness and atrophy does not have a homogeneous distribution. The severity of muscle weakness is related to age at onset and children with the most severe form of the disease (Type I SMA) can appear normal at birth, but present muscle weakness a few months later.8
Furthermore, the clinical course followed by SMA patients who survive beyond childhood demonstrates that loss of muscle strength is normally most evident at diseases onset and that, after this, residual muscle power can remain stable for months or years.12,13
Molecular genetic basis of SMA
Genetic studies have shown that SMA is caused by absence of the SMN1 gene, which should be located in the telomeric region of chromosome 5.12,14,15 This gene was identified in 1995 by Lefebvre et al.16 and has nine exons that code for the SMN protein. All patients still retain at least one copy of a very similar gene - SMN2 which is located in the centromeric part of the same chromosome. The absence of SMN1 is caused either by a deletion or by a conversion that transforms SMN1 into SMN27 (Figure 1).
The SMN1 gene is responsible for complete synthesis of the SMN protein. In contrast, the SMN2 gene is not capable of completely synthesizing the protein, being only responsible for a part of its production. SMN2 produces 10 to 25% functional protein while the remaining 75% produced is a protein that is truncated and unstable (SMN∆7) and is rapidly degraded (Figure 1).10,15,17,18
Another important point that should be highlighted is that the number of intact copies of SMN2 is a determinant of disease severity. Figure 2 illustrates the genotype of people who are affected and unaffected by SMA, characterizing type I, II and III patients. It also illustrates the quantity of SMN protein synthesized by each genotype. As the number of copies of SMN2 increases, the quantity of functional SMN protein increases and the severity of the disease reduces.5,7,10,19 The figure also demonstrates that gene conversion events are responsible for the milder phenotypes, while deletion of the SMN1 gene leads to more severe forms of the AME.7,20,21
The SMN protein is widely distributed in all cells of the body.18,22 It is found in the nuclei of cells and within the nucleus it binds to certain structures involved with removing non-coding sequences (introns) from the pre-MRNA (messenger ribonucleic acid). Furthermore, it appears that SMN also participates in regulating transcription and expression of certain genes.10,18
Despite advances in knowledge about the biochemistry of SMN, it is not yet clear how reduced levels in all different cell types are specifically responsible for degeneration of a motor neurons. This raises the possibility that SMN has an additional function that is restricted to these neurons. Immunohistochemical studies have identified SMN in dendrites, implantation cones and axons of motor neurons, suggesting it plays a role in transporting RNA along axons.10 Furthermore, it has been observed that the motor neurons of SMN-knockout mice and zebrafish exhibit failure to reach the motor end plate, having an axon with aberrant ramifications, indicating strong evidence that SMN plays an important role in morphological development and axonal migration.23 On the other hand, the SMN protein is also found postsynaptically at the neuromuscular junction and in the Z bands of striated muscle, indicating that pathogenesis does not exclusively involve the motor neuron cell body, but can also affect the muscle fibers themselves.24
No cases have ever been reported of people with complete absence of the SMN protein, i.e., patients who have SMA and also have an absent SMN2 gene. This is probably because such a genotype would be incompatible with life and the SMN protein may play an essential role during embryo development19,25,26 or may modulate neuronal apoptosis.27
Since SMA is a low-incidence neurological disorder, diagnosis is difficult. Nevertheless, since SMA develops progressively, rapidly establishing a precise diagnosis is essential.
Children manifesting clinical signs characteristic of SMA, such as hypotonia, paresis, areflexia and fasciculation, should be investigated with care,1 since these clinical signs can also be observed in other neuropathologies (Table 1).
Since neuromuscular diseases are the main causes of childhood hypotonia28 and since the neuromuscular diseases that most often affect children are SMA and the dystrophies,28,29 Table 230 provides a summary of the principal features that differentiate between the two groups. Notwithstanding, it should be pointed out that not all of the features described here will always be present in every patient, since they vary according to the disease stage that each patient is in at the time of assessment.
In general, diagnosis of SMA is made on the basis of evidence of muscle denervation, found on electromyography and in muscle biopsy.3 Diagnosis is confirmed by molecular analysis demonstrating that exon 7 of the SMN1 gene is absent, irrespective of clinical classification.2
Creatine phosphokinase (CPK) may be normal or as much as five times lower than normal.1 Serum CPK can differentiate neurogenic diseases, of which SMA is one, from myopathic diseases, such as dystrophies, in which muscle damage raises CPK levels.
Electromyography can be used to determine whether the disease has affected motor neurons, nerve roots, peripheral nerves, myoneural junction or muscle fibers.29
In SMA there is electrophysiological evidence of denervation, while conduction is found to be intact in motor and sensory nerves.1,10 Fibrillation potentials are observed at rest in cases of denervation, whether located in the anterior horn or peripheral nerves, both duration and amplitude of motor unit potentials may be increased and there may be a reduction in motor conduction velocity in the earlier forms of AME.1
A range of abnormal muscle features can be observed in SMA patients. Certain histopathological findings are characteristic, such as the presence of atrophic muscle fibers, both type I and type II, hypertrophy of type I fibers or fiber-type grouping.1,10 However, these findings can also be observed in other causes of denervation.31 Therefore, this type of test does not confirm SMA, but provides additional clinical data.
In the slower-progressing forms, superimposition of secondary myopathic abnormalities, such as angular fibers, central nuclei, splits and myofibrillar disarrangement, increase as the disease progresses.32
Molecular genetic tests provide definitive diagnosis of SMA and could be the only tests performed. Genetic investigation demonstrates that exon 7 of the SMN1 gene is completely absent (with or without a deletion of exon 8).2,8 Since the SMN2 gene does not have this exon, its absence also demonstrates that the SMN1 gene is nullified.
If a patient suspected of having SMA does have a copy of the SMN1 gene, then this copy should be investigated for mild mutations such as point mutations, insertions and deletions leading to a homozygous dysfunction of the gene.8
Molecular genetic diagnosis is more precise and less invasive than the other two tests described, but it is not widely available in Brazil. It should be pointed out that testing for deletions in the SMN gene can provide guidance during cases in which diagnosis is uncertain.1
Alternatively, Kolb et al.33 developed a technique for measuring the SMN protein in mononuclear cells (lymphocytes and monocytes), obtained from blood samples from patients with SMA. As would be expected, SMN protein levels were significantly reduced in the patients in comparison with the controls. The authors33 stated that their test could be used in the future to monitor clinical trials attempting to increase levels of MRNA and/or the SMN protein itself, but that it is not the best choice for diagnosing SMA.
Since it is a progressive neurodegenerative pathology, SMA patients require a range of special treatments that can halt the disease's progress and prolong their lives. The majority of care revolves around supportive therapies because, unfortunately, there is not yet any pharmacological treatment.
A multidisciplinary team is responsible for prolonging and improving the quality of patients' lives.24 Care covers respiratory and nutritional support in addition to orthopedic and physiotherapeutic care, to avert postural problems.
a) Respiratory care:
Pulmonary diseases are the principal cause of morbidity and mortality among patients with SMA types I and II and can affect a small number of patients with type III SMA.8
The severity of muscle weakness and the fact that these patients are either always lying down or get up very little mean that they have a limited capacity to cough and remove secretions from the lower respiratory tract. As a result of this they are prone to recurrent infections which exacerbate the muscle weakness (particularly of the respiratory muscles),8 and can lead to atelectasis and pulmonary collapse.24 Additionally, these children may suffer from nocturnal hypoventilation and underdevelopment of the lungs and chest wall.8,24
Provision for these patients includes rapid access to special clinical intervention and respiratory support when necessary (ranging from noninvasive ventilation to tracheostomy and mechanical ventilation). Techniques for cleaning the Airways and moving secretions are very useful, including pulmonary physiotherapy and postural drainage. These patients also need rapid access to antibiotic therapy and should be on an immunization schedule including several vaccines against agents that can cause severe pulmonary infections.8,24,34
Both atrophy and hypotonia of the muscles have a direct influence on the degree of compromise to respiratory and motor function. In these situations it is the physiotherapist who works to prevent and treat bone deformities and respiratory disorders, contributing to preventing the disease from progressing and to improving patients' quality of life.13
b) Nutritional care:
Children with SMA can suffer from a variety of gastrointestinal problems, such as gastroesophageal reflux, constipation, abdominal distension and retarded gastric emptying.8,24 Reflux is a determinant of mortality and morbidity, because it can be associated with silent aspiration, which can lead to aspiration pneumonia, worsening the situation even further. High fat foods should be avoided because they delay gastric emptying and increase the risk that reflux will occur.8
The origins of constipation are multifactorial and it may be the result of abnormal gastrointestinal tract motility, reduced intake of foods rich in fibers and of water and also hypotonicity of muscles in the abdominal wall.8,34 Furthermore, in these patients reduced intestinal movement can result in abdominal distension.8
Patient care includes pharmacological treatment for gastroesophageal reflux, involving gastric acid neutralizers and/or gastric secretion inhibitors, such as proton pump inhibitors and histamine blockers,8 in addition to prokinetic agents.24
Diet can be assessed by a nutritionist. It should be remembered that SMA patients may have an acceptable fat mass for their body, but may be classified as below normal weight, on the weight/height criterion, because of their reduced body mass. This could lead to inappropriate dietary advice, which would in turn lead to obesity.8
In severe cases, where children are unable to feed sufficiently enterally, parenteral calorie supplementation should be considered in order to avoid muscle catabolism in children with low fat reserves.8
c) Orthopedic care:
The principal problem that result from the limited trunk and limb motor function caused by the muscle weakness include postural deformities (scoliosis), limitations to mobility and the ability to carry out daily activities, increased risk of pain, osteopenia and fractures.4,8,24 Iannaccone34 reports that scoliosis is rare before early childhood, and so is not normally seen in children with Type I SMA, but is common in patients with Type II SMA and less common in those with Type III. Weakness of the paraspinal muscles means that scoliosis progresses gradually and should be monitored regularly.24
Patients with Type I SMA also have difficulties related to limited head control, posture and alignment. The principal problems among Type II patients are contractures, respiratory dysfunction and scoliosis. The combination of proximal muscle weakness and impaired balance means that patients with Type III SMA fall frequently and suffer abnormal fatigue during physical activity.8
Interventions that can be employed to avoid worse consequences are postural control, pain control and contracture control, adaptation of daily activities, mobility with a wheelchair or walking frame, ortheses for limbs and therapies that encourage the development of mobility, prolonging these children's survival and alleviating the burden of the disease.8
Regular exercise, such as swimming or other appropriate sports, is important to recover the self-esteem of these children, to introduce them into a social context and to help maintain physical fitness. Swoboda et al.13 report that regular physical exercise can be helpful to develop muscles and joints, increase bone density, improve intestinal mobility and promote a general sense of wellbeing.
Grondard et al.35 studied the benefits of regular exercise in mutant rats with Type II SMA and found positive results. They noted that mutant rats that were forced to run in a wheel exhibited an impressive increase in survival time, compared with non-exercised rats, and they also observed a reduction in medullary motor neuron death. These results suggest that regular physical exercises should be combined with pharmacological treatment in order to test the possibility of cumulative protective effects against disease progression.
Finally, Oskoui & Kaufmann24 point out that modifications need to be made to the homes of these children in order to guarantee their safety and allow them independence.
Sadly, there is currently no pharmacological treatment available for SMA. However, on the basis of progress in understanding the genetic bases and the pathophysiology of SMA, potential candidates to attempt to treat it are emerging.36,37 Some drugs that are being tested for treatment of SMA patients have as their therapeutic targets the SMN2 gene. Strategies that increase its transcription or that stabilize the protein it forms appear to be promising.37,38 Some drugs based on this therapeutic perspective are described below.
a) Histone deacetylase inhibitors:
This class of drugs has been investigated for treatment of SMA because of its ability to activate transcription of the SMN2 gene, because when histone is acetylated (inhibited histone deacetylase), transcription factors become more accessible to several genes (including SMN2), encouraging their transcription.
Clinically known drugs, such as valproic acid, sodium butyrate and phenylbutyrate are examples of compounds that have an inhibitory action on the histone deacetylase enzyme. This property makes them potential candidates for treatment of SMA, particularly valproic acid17,38,39 and phenylbutyrate,40 which are better able to penetrate the CNS, in addition to the fact that their pharmacokinetics and safety profiles have already been described.
Valproic acid is the histone deacetylase inhibitor that has been most investigated in preclinical and clinical trials assessing its efficacy for treating SMA.17,38,39 The efficacy of valproic acid to induce an increase in the levels of the SMN protein has been demonstrated in cultures of fibroblasts from patients with SMA I,17,39 in hippocampus slices39 and in motor neuron cultures38 from an SMA I rat model. In vivo, administration of valproic acid in the drinking water of a mouse model of SMA III, increased SMN protein levels in spinal marrow and also improved motor function, with increased evoked motor potentials, reduced spinal marrow neuron degeneration and better innervation of the neuromuscular junction when compared with control SMA animals.41
After these encouraging preclinical results, clinical trials were started. Non-randomized and non-placebo-controlled clinical studies by Tsai et al.42 and Weihl et al.43 with small numbers of patients demonstrated a modest improvement in muscle strength and subjective function. These studies used the same dosage of valproic acid that is recommended for the treatment of epilepsy (15 to 50 mg/kg/day). Recently, Swoboda et al.44 published the first phase II clinical trial of valproic acid (15 to 50 mg/kg/day), given to 42 patients with Type I, II or III SMA aged from 2 to 31 years. The results are to a certain extent inconclusive, probably because of the heterogeneous nature of the sample, and it was not possible to detect a clear interference in disease progression caused by the drug. Some patients suffered weight gain and carnitine depletion. The authors themselves44 stressed the need for randomized, placebo-controlled and double-blind clinical trials that would be capable of a more accurate investigation of the efficacy of valproic acid for SMA treatment.
A study conducted by Rak et al.,38 that is still in prepublication for the journal Neurology of Disease, showed that cultures of motor neurons from mice with SMA I that were treated with valproic acid also increased SMN protein expression. However, unexpectedly, they observed a reduction in the excitability of axonal terminals, caused by an inhibitory effect of the drug on voltage dependent Ca+2 channels and, possibly in other channels that contribute to motor neuron excitability. On the basis of these findings, the authors warn that valproic acid could aggravate certain symptoms of the disease in SMA patients.
Other drugs that are in preclinical or clinical phases are hydroxyurea37,45 and the quinazolines,37 which have the capacity to activate SMN2 gene transcription through mechanisms that do not interfere in histone deacetylase enzyme activity.
b) Drugs to stabilize the SMN∆7 protein:
This group includes indoprofen46 (non-steroidal anti-inflammatory) and some aminoglycosides antibiotics, such as amikacin and tobramycin.47 These drugs have the capacity to increase the efficiency of the translation process of the protein derived from the SMN2 gene, leading to a more stable protein. Unfortunately, both indoprofen and aminoglycosides penetrate the CNS poorly.37 The synthesis of compounds that retain the stabilizing property, but are able to pass the hematoencephalic barrier is awaited with great expectation.
Future prospects for diagnosis and treatment of SMA
There are still several unknowns relating to SMA that need to be elucidated. Wang et al.8 predicted that, based on recent therapeutic advances, it is possible that in the future SMA will be treated more effectively in presymptomatic patients, diagnosed as soon as the disease begins to develop, so that the clinical course is interrupted before muscle weakness becomes evident.
Preliminary data from electrophysiological studies that included estimation of motor units in children with SMA suggest that motor neuron loss is most significant during the postnatal period for the majority of patients.13 Therefore, exams should be implemented for neonatal diagnosis, or even for prenatal detection, in order to anticipate access to special medical care. Wirth et al.10 report that families at risk of having a child with SMA can be offered a prenatal diagnostic test based on analysis of chorionic villi (10th and 12th week) or amniotic fluid (14th and 16th week of pregnancy).
In Brazil, the Centro de Estudos do Genoma Humano, Universidade de São Paulo (CEGH-USP), offers prenatal diagnosis to couples who have already had one child with SMA, since at every pregnancy they run a 25% risk of having another child with the same disease. A positive diagnosis of genetic disease should not be interpreted as the determining factor for terminating a pregnancy, but as a signal to introduce treatment before the baby develops symptoms related to the condition.
Therefore, it is also worth commenting that prenatal diagnosis is worthless if there is no adequate treatment that offers a positive response without provoking deleterious side-effects whether for the expectant mother or for her child. However, this will only be possible once there is a universal plan for newborn infants, the necessary infrastructure to enroll them on clinical trials and approved ethical regulations for treatment of these presymptomatic children.24
The use of stem cells is being studied as a promising cellular source for treatment of disorders related to the loss of these exclusive cells, as is the case of SMA.48 It is important to remember that there are many obstacles that researchers need to overcome in order to confirm effective use of stem cells. Among these are: the production of a large quantity of differentiated motor neurons from stem cells49; survival of partially differentiated cells in the nervous system after implantation; cells must have the capacity to extend axons and create synapses; and, lastly, they must all lead to significant functional recovery.24 Thus, in the not so near future stem cells may be used for recuperation in neuromuscular diseases.
Finally, substances with a neuroprotective action, (such as cardiotrophin-1),50 and genetic conversion of the SMN2 gene into SMN1,51 are also the subject of therapeutic proposals being studied.
Both medical follow-up and palliative care are important throughout SMA patients' entire lives. This care includes respiratory and nutritional support, and orthopedic and physiotherapeutic care to avoid postural disorders. In addition to this we can cite pharmacological treatments that are still being studied, both employing new drugs and drugs that are already well-known.
It cannot be expected that the pharmacological treatments currently being studied can recover motor neurons or muscle cells that have already been lost to atrophy. Rather, the objective is to retard the progress of the disease and improve residual muscle function. Sadly, paralysis can be halted, but it cannot be reversed. However, through a combination of medical care and rehabilitation, many patients with SMA can have fulfilling and productive lives and often have normal life expectancy.
Finally, there is one other point it is important to emphasize, which is that since SMA is a recessive genetic disorder, genetic counseling is an essential component for the families of these patients. Through genetic counseling, parents, who are carriers of SMA, should be encouraged to be cautious when planning future pregnancies because the risk of having children with the same heritage does not go away.
1. Araújo AP, Ramos VG, Cabello PH. Dificuldades diagnósticas na atrofia muscular espinhal. Arq Neuropsiquiatr. 2005;63:145-9. [ Links ]
2. Prior TW. Spinal muscular atrophy diagnostics. J Child Neurol. 2007;22:952-6. Review. [ Links ]
3. Russman BS. Spinal muscular atrophy: clinical classifications and disease heterogeneity. J Child Neurol. 2007;22:946-51. [ Links ]
4. Shanmugarajan S, Swoboda KJ, Iannaccone ST, Ries WL, Maria BL, Reddy SV. Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling. J Child Neurol. 2007;22:967-73. [ Links ]
5. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358-68. [ Links ]
6. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001;98:9808-13. [ Links ]
7. Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet. 1997;61:40-50. [ Links ]
8. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22:1027-49. [ Links ]
9. Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, De Vivo DC, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931-6. [ Links ]
10. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy: from gene to therapy. Semin Pediatr Neurol. 2006;13:121-31. Review. [ Links ]
11. Zerres K, Rudnik-Schöneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518-23. [ Links ]
12. Sumner CJ. Molecular mechanisms of spinal muscular atrophy. J Child Neurol. 2007;22:979-89. [ Links ]
13. Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G, D'Anjou G, et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol. 2007;22:957-66. [ Links ]
14. Heier CR, Gogliotti RG, DiDonato CJ. SMN transcript stability: could modulation of messenger RNA degradation provide a novel therapy for spinal muscular atrophy? J Child Neurol. 2007;22:1013-8. [ Links ]
15. Meldrum C, Scott C, Swoboda KJ. Spinal muscular atrophy genetic counseling access and genetic knowledge: parents' perspestives. J Child Neurol. 2007;22:1019-26. [ Links ]
16. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155-65. [ Links ]
17. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovet DD, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54:647-54. [ Links ]
18. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10:597-609. [ Links ]
19. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet. 2000;9:333-9. [ Links ]
20. Burghes AH. When is a deletion not a deletion? When it is converted. Am J Hum Genet. 1997;61:9-15. Review. [ Links ]
21. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, Mendell JR, et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997;60:1411-22. [ Links ]
22. Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6:1205-14. [ Links ]
23. McWhorter ML, Monani UR, Burghes AH, Beattie CE. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol. 2003;162:919-31. [ Links ]
24. Oskoui M, Kaufmann P. Spinal muscular atrophy. Neurotherapeutics. 2008;5:499-506. Review. [ Links ]
25. Kolb SJ, Battle DJ, Dreyfuss G. Molecular functions of the SMN complex. J Child Neurol. 2007;22:990-4. [ Links ]
26. Beattie CE, Carrel TL, Mcwhorter ML. Fishing for a mechanism: using zebrafish to understand spinal muscular atrophy. J Child Neurol. 2007;22:995-1003. [ Links ]
27. Kerr DA, Nery JP, Traystman RJ, Chau BN, Hardwick JM. Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci U S A. 2000;97:13312-17. [ Links ]
28. Diz MA, Diz MC. Hipotonia na infância. An Prod Acad Doc. 2007;1:184-9. [ Links ]
29. Reed UC. Doenças neuromusculares. J Pediatr (Rio J). 2002;78 Suppl 1:S89-S103. [ Links ]
30. ABRAME Associação Brasileira de Amiotrofia Espinhal. Diferenças entre Atrofias e Distrofias. http://www.atrofiaespinhal.org/oque_atrofia_distrofia.php. Acessado em: 12/05/2008. [ Links ]
31. Pons R, Andreetta F, Wang CH, Vu TH, Bonilla E, DiMauro S, et al. Mitochondrial myopathy simulating spinal muscular atrophy. Pediatr Neurol. 1996;15:153-8. [ Links ]
32. Mastaglia FL, Walton JN. Histological and histochemical changes in skeletal muscle from cases of chronic juvenile and early adult spinal muscular atrophy (the Kugelberg-Welander syndrome). J Neurol Sci. 1971;12:15-44. [ Links ]
33. Kolb SJ, Gubitz AK, Olszewski RF Jr, Ottinger E, Sumner CJ, Fischbeck KH, et al. A novel cell imunoassay to measure survival of motor neurons protein in blood cells. BMC Neurol. 2006;6:6. [ Links ]
34. Iannaccone ST. Modern management of spinal muscular atrophy. J Child Neurol. 2007;22:974-8. [ Links ]
35. Grondard C, Biondi O, Armand AS, Lécolle S, Della Gaspera BD, Pariset C, et al. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J Neurosci. 2005;25:7615-22. [ Links ]
36. Lunke S, El-Osta A. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. J Neurochem. 2009;109:1557-69. [ Links ]
37. Sumner CJ. Therapeutics development for spinal muscular atrophy. NeuroRx. 2006;3:235-45. Review. [ Links ]
38. Rak K, Lechner BD, Schneider C, Drexl H, Sendtner M, Jablonka S. Valproic acid blocks excitability in SMA type I mouse motor neurons. Neurobiol Dis. 2009;36:477-87. [ Links ]
39. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003;12:2481-9. [ Links ]
40. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, Borgo F, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet. 2005;13:256-9. [ Links ]
41. Tsai LK, Tsai MS, Ting CH, Li H. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med. 2008;86:1243-54. [ Links ]
42. Tsai LK, Yang CC, Hwu WL, Li H. Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol. 2007;14:e8-9. [ Links ]
43. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology. 2006;67:500-1. [ Links ]
44. Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson Sl, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009;4:e5268. [ Links ]
45. Liang WC, You CY, Chang JG, Chen YC, Chang YF, Wang HY, et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci. 2008;268:87-94. [ Links ]
46. Lunn MR, Root DE, Martino AM, Flaherty SP, Kelley BP, Coovert DD, et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol. 2004;11:1489-93. [ Links ]
47. Wolstencroft EC, Mattis V, Bajer AA, Young PJ, Lorson CL. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet. 2005;14:1199-210. [ Links ]
48. Lee H, Shamy GA, Elkabetz Y, Schofield CM, Harrsion NL, Panagiotakos G, et al. Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells. 2007;25:1931-9. [ Links ]
49. Nayak MS, Kim YS, Goldman M, Keirstead HS, Kerr DA. Cellular therapies in motor neuron diseases. Biochim Biophys Acta. 2006;1762:1128-38. [ Links ]
50. Lesbordes JC, Cifuentes-Diaz C, Miroglio A, Joshi V, Bordet T, Kahn A, et al. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2003;12:1233-9. [ Links ]
51. DiMatteo D, Callahan S, Kmiec EB. Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy. Exp Cell Res. 2008;314:878-86. [ Links ]
Correspondence: Manuscript submitted Aug 26 2009, accepted for
publication Oct 14 2009. No conflicts of interest declared concerning
the publication of this article
Celia Regina Ambiel
Rua Carlos Roberto Seghezzi 668
CEP 87140-000 - Paiçandu, PR - Brazil
Manuscript submitted Aug 26 2009, accepted for publication Oct 14 2009.
No conflicts of interest declared concerning the publication of this article